Establishment Labs (NASDAQ:ESTA) Trading 7.1% Higher - What's Next?

Key Points

• Establishment Labs Holdings Inc. saw its share price increase by 7.1% to $44.09, despite a significant drop in trading volume of 87% from its average.
• Recent analyst ratings include a downgrade from Wall Street Zen to a "sell" rating, while Mizuho raised their price target to $70.00, reflecting a mixed outlook for the company.
• The company reported a quarterly earnings miss with an EPS of ($0.57), which was below the consensus estimate, though revenue increased by 16.1% year-over-year.

Establishment Labs Holdings Inc. (NASDAQ:ESTA - Get Free Report)'s share price was up 7.1% during trading on Tuesday . The stock traded as high as $43.93 and last traded at $44.09. Approximately 60,584 shares traded hands during trading, a decline of 87% from the average daily volume of 480,801 shares. The stock had previously closed at $41.16.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Wall Street Zen downgraded Establishment Labs from a "hold" rating to a "sell" rating in a research report on Saturday. Mizuho raised their price target on Establishment Labs from $58.00 to $70.00 and gave the stock an "outperform" rating in a report on Wednesday, July 16th. Canaccord Genuity Group started coverage on Establishment Labs in a research note on Wednesday, August 20th. They issued a "buy" rating and a $60.00 price objective for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Establishment Labs in a research report on Wednesday, October 8th. Finally, Citigroup reaffirmed a "neutral" rating on shares of Establishment Labs in a research note on Tuesday, October 7th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $56.50.

Establishment Labs Price Performance

The company has a current ratio of 2.84, a quick ratio of 1.67 and a debt-to-equity ratio of 9.71. The company's 50 day moving average price is $39.57 and its 200 day moving average price is $38.01. The company has a market cap of $1.31 billion, a price-to-earnings ratio of -14.79 and a beta of 0.85.

Establishment Labs (NASDAQ:ESTA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.54) by ($0.03). The firm had revenue of $51.30 million for the quarter, compared to analyst estimates of $50.80 million. Establishment Labs had a negative return on equity of 224.34% and a negative net margin of 49.89%.The business's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.62) earnings per share. Establishment Labs has set its FY 2025 guidance at EPS. Equities research analysts forecast that Establishment Labs Holdings Inc. will post -2.41 earnings per share for the current year.

Institutional Trading of Establishment Labs

Institutional investors and hedge funds have recently bought and sold shares of the company. Nantahala Capital Management LLC grew its holdings in shares of Establishment Labs by 7.2% during the first quarter. Nantahala Capital Management LLC now owns 1,774,044 shares of the company's stock valued at $72,390,000 after purchasing an additional 119,574 shares during the last quarter. Tyro Capital Management LLC lifted its position in shares of Establishment Labs by 0.3% during the 2nd quarter. Tyro Capital Management LLC now owns 1,066,721 shares of the company's stock valued at $45,560,000 after acquiring an additional 2,835 shares during the last quarter. Bamco Inc. NY lifted its holdings in shares of Establishment Labs by 21.5% in the second quarter. Bamco Inc. NY now owns 907,537 shares of the company's stock valued at $38,761,000 after purchasing an additional 160,755 shares in the last quarter. William Blair Investment Management LLC lifted its holdings in shares of Establishment Labs by 2.1% in the second quarter. William Blair Investment Management LLC now owns 865,244 shares of the company's stock valued at $36,955,000 after purchasing an additional 17,855 shares in the last quarter. Finally, Rice Hall James & Associates LLC increased its stake in shares of Establishment Labs by 7.4% in the first quarter. Rice Hall James & Associates LLC now owns 827,423 shares of the company's stock worth $33,763,000 after acquiring an additional 56,756 shares during the last quarter. Institutional investors and hedge funds own 72.91% of the company's stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.